Símbolos

AInvest★★★★★3-DAY FREE

Catch pre-market movers with AI signals.

Claim Trial

CPRX(Quitar la ciudad)

Catalyst·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CPRX

Catalyst Pharmaceuticals, Inc.

A commercial-stage biopharmaceutical company that develops prescription drugs for neuromuscular and neurological diseases and disorders

Industry

Established Date

Listing Date

11/08/2006

Exchange

NASDAQ Stock Exchange

Full-time Employees

182

Fiscal Year Ends

12-31

Website

www.catalystpharma.com

Security Type

Common stock

Office address

355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134

Business

Develops and commercializes medicines.

Introduction

Catalyst Pharmaceuticals, Inc., was incorporated in Delaware in July 2006. The Company is a commercial-stage, patient-centric biopharmaceutical company focused on the licensing, development and commercialization of new high-quality medicines for patients with rare and difficult-to-treat diseases. The company uses a concerted and diligent effort to find therapies that can improve the lives of those with rare or difficult-to-treat diseases.

Company Financials

EPS

CPRX has released its 2026 Q1 earnings. EPS was reported at 0.5, versus the expected 0.44, beating expectations. The chart below visualizes how CPRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CPRX has released its 2026 Q1 earnings report, with revenue of 149.39M, reflecting a YoY change of 5.63%, and net profit of 63.73M, showing a YoY change of 12.33%. The Sankey diagram below clearly presents CPRX's revenue sources and cost distribution.